Induction (proto) chemotherapy consisting of 3 courses of cisplatin and 120-hour 5-fluorouracil infusion was administered to 88 patients who had locally advanced, previously untreated head and neck cancer. The majority (81%) of these patients were classified as stage IV, and 17% had second primary c
β¦ LIBER β¦
Intraarterial chemotherapy through carotid transposition in advanced head and neck cancer
β Scribed by Francesco Claudio; Francesco Cacace; Giusepppe Comella; Francesco Coucourde; Luigi Claudio; Anna Maria Bevilacqua; Salvatore Toma
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 678 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Photo-chemotherapy in advanced head and
β
Jacobs, John R. ;Weaver, Arthur ;Ahmed, Khurshid ;Crissman, John ;Ensley, John F
π
Article
π
1987
π
Wiley (John Wiley & Sons)
β 526 KB
A pilot study of intraarterial chemother
A pilot study of intraarterial chemotherapy with cisplatin in locally advanced head and neck cancers
β
Dominic K. Cheung; Joseph Regan; Michael Savin; Val Gibberman; William Woessner
π
Article
π
1988
π
John Wiley and Sons
π
English
β 523 KB
Editorial. Induction chemotherapy for ad
β
Hong, Waun K.
π
Article
π
1988
π
Wiley (John Wiley & Sons)
β 246 KB
π 2 views
Chemotherapy in the treatment of locally
β
Arlene A. Forastiere
π
Article
π
2008
π
John Wiley and Sons
π
English
β 99 KB
π 1 views
Chemotherapy trials in head and neck can
β
Samuel G. Taylor IV; Arlene A. Forastiere
π
Article
π
1996
π
John Wiley and Sons
π
English
β 223 KB
π 2 views
Intraarterial infusion chemotherapy for
β
Baker, Shan R. ;Wheeler, Richard H. ;Ensminger, William D. ;Niederhuber, John E.
π
Article
π
1981
π
Wiley (John Wiley & Sons)
β 569 KB
## Abstract Intraarterial infusion chemotherapy has not been widely accepted for the treatment of head and neck cancer due to the high rate of complications it involves. To avoid these complications, a totally implantable infusion pump has been developed to achieve continuous lowβlevel drug deliver